{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:24:03Z","timestamp":1767900243192,"version":"3.49.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Natural Science Foundation of Shenzhen City","award":["No.JCYJ20230807141759001,JCYJ20220530162204009,JCYJ20180306170407292 to Fa-Qing Tian"],"award-info":[{"award-number":["No.JCYJ20230807141759001,JCYJ20220530162204009,JCYJ20180306170407292 to Fa-Qing Tian"]}]},{"name":"he Special Fund Project for Economic and Technological Development of Longgang District, Shenzhen","award":["No. LGKCYLWS2021000008 to Fa-Qing Tian"],"award-info":[{"award-number":["No. LGKCYLWS2021000008 to Fa-Qing Tian"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"DOI":"10.1007\/s00011-025-02151-z","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T13:45:40Z","timestamp":1767879940000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Knockdown of caspase-activated DNase and B-cell lymphoma 2 inhibits cell proliferation and drug resistance in TP53-mutant multiple myeloma"],"prefix":"10.1007","volume":"75","author":[{"given":"Faqing","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiqin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaoyang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoxin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"5","key":"2151_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377.","journal-title":"JAMA"},{"issue":"1","key":"2151_CR2","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1038\/s41467-022-31248-w","volume":"13","author":"J Xia","year":"2022","unstructured":"Xia J, et al. Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance. Nat Commun. 2022;13(1):4007.","journal-title":"Nat Commun"},{"key":"2151_CR3","doi-asserted-by":"publisher","first-page":"101168","DOI":"10.1016\/j.blre.2024.101168","volume":"64","author":"SE Clarke","year":"2024","unstructured":"Clarke SE, Fuller KA, Erber WN. Chromosomal defects in multiple myeloma. Blood Rev. 2024;64:101168.","journal-title":"Blood Rev"},{"issue":"9","key":"2151_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41408-022-00719-0","volume":"12","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV, et al. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J. 2022;12(9):129.","journal-title":"Blood Cancer J"},{"issue":"3","key":"2151_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up(dagger). Ann Oncol. 2021;32(3):309\u201322.","journal-title":"Ann Oncol"},{"key":"2151_CR6","doi-asserted-by":"publisher","first-page":"102284","DOI":"10.1016\/j.ctrv.2021.102284","volume":"100","author":"P Rodriguez-Otero","year":"2021","unstructured":"Rodriguez-Otero P, Paiva B. San-Miguel, Roadmap to cure multiple myeloma. Cancer Treat Rev. 2021;100:102284.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"2151_CR7","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","volume":"115","author":"I Hanamura","year":"2022","unstructured":"Hanamura I. Multiple myeloma with high-risk cytogenetics and its treatment approach. Int J Hematol. 2022;115(6):762\u201377.","journal-title":"Int J Hematol"},{"issue":"6","key":"2151_CR8","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/ajh.26507","volume":"97","author":"EA Rojas","year":"2022","unstructured":"Rojas EA, et al. Expression of p53 protein isoforms predicts survival in patients with multiple myeloma. Am J Hematol. 2022;97(6):700\u201310.","journal-title":"Am J Hematol"},{"issue":"6","key":"2151_CR9","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.3892\/or.2017.5609","volume":"37","author":"R He","year":"2017","unstructured":"He R, et al. Identification and expression of MMSA-8, and its clinical significance in multiple myeloma. Oncol Rep. 2017;37(6):3235\u201343.","journal-title":"Oncol Rep"},{"issue":"5","key":"2151_CR10","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s41418-022-00962-9","volume":"29","author":"Z Wang","year":"2022","unstructured":"Wang Z, Strasser A, Kelly GL. Should mutant TP53 be targeted for cancer therapy? Cell Death Differ. 2022;29(5):911\u201320.","journal-title":"Cell Death Differ"},{"issue":"2","key":"2151_CR11","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1016\/S2352-3026(22)00355-6","volume":"10","author":"TE Lew","year":"2023","unstructured":"Lew TE, et al. Treatment approaches for patients with TP53-mutated mantle cell lymphoma. Lancet Haematol. 2023;10(2):e142\u201354.","journal-title":"Lancet Haematol"},{"issue":"12","key":"2151_CR12","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1158\/2767-9764.CRC-23-0350","volume":"3","author":"D Juarez","year":"2023","unstructured":"Juarez D, et al. Statin-induced mitochondrial priming sensitizes multiple myeloma cells to BCL2 and MCL-1 inhibitors. Cancer Res Commun. 2023;3(12):2497\u2013509.","journal-title":"Cancer Res Commun"},{"issue":"9","key":"2151_CR13","doi-asserted-by":"publisher","first-page":"e2104491","DOI":"10.1002\/advs.202104491","volume":"9","author":"X Feng","year":"2022","unstructured":"Feng X, et al. Genetic aberrations and interaction of NEK2 and TP53 accelerate aggressiveness of multiple myeloma. Adv Sci (Weinh). 2022;9(9):e2104491.","journal-title":"Adv Sci (Weinh)"},{"key":"2151_CR14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41408-020-00395-y","volume":"11","author":"VA Gupta","year":"2021","unstructured":"Gupta VA, et al. BCL2 family inhibitors in the biology and treatment of multiple myeloma. Blood Lymphat Cancer. 2021;11:11\u201324.","journal-title":"Blood Lymphat Cancer"},{"key":"2151_CR15","doi-asserted-by":"publisher","first-page":"110405","DOI":"10.1016\/j.cbi.2023.110405","volume":"374","author":"SS de Souza","year":"2023","unstructured":"de Souza SS, et al. Malathion alters the transcription of target genes of the tumour suppressor tp53 and cancerous processes in colossoma macropomum: mechanisms of DNA damage response, oxidative stress and apoptosis. Chem Biol Interact. 2023;374:110405.","journal-title":"Chem Biol Interact"},{"issue":"1","key":"2151_CR16","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.1038\/s41467-023-40087-2","volume":"14","author":"H Wei","year":"2023","unstructured":"Wei H, et al. Structures of p53\/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity. Nat Commun. 2023;14(1):4300.","journal-title":"Nat Commun"},{"issue":"7","key":"2151_CR17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s41418-024-01320-7","volume":"31","author":"A Moeed","year":"2024","unstructured":"Moeed A, et al. The Caspase-Activated DNase drives inflammation and contributes to defense against viral infection. Cell Death Differ. 2024;31(7):924\u201337.","journal-title":"Cell Death Differ"},{"issue":"10","key":"2151_CR18","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.tcb.2023.03.002","volume":"33","author":"J Benada","year":"2023","unstructured":"Benada J, et al. Self-inflicted DNA breaks in cell differentiation and cancer. Trends Cell Biol. 2023;33(10):850\u20139.","journal-title":"Trends Cell Biol"},{"issue":"4","key":"2151_CR19","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.molcel.2022.01.001","volume":"82","author":"KF Meza-Sosa","year":"2022","unstructured":"Meza-Sosa KF, et al. SPARCLE, a p53-induced lncRNA, controls apoptosis after genotoxic stress by promoting PARP-1 cleavage. Mol Cell. 2022;82(4):785\u2013e80210.","journal-title":"Mol Cell"},{"issue":"638","key":"2151_CR20","doi-asserted-by":"publisher","first-page":"eabc7480","DOI":"10.1126\/scitranslmed.abc7480","volume":"14","author":"M Ali","year":"2022","unstructured":"Ali M, et al. Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells. Sci Transl Med. 2022;14(638):eabc7480.","journal-title":"Sci Transl Med"},{"issue":"6592","key":"2151_CR21","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1126\/science.abi6378","volume":"376","author":"BD Larsen","year":"2022","unstructured":"Larsen BD, et al. Cancer cells use self-inflicted DNA breaks to evade growth limits imposed by genotoxic stress. Science. 2022;376(6592):476\u201383.","journal-title":"Science"},{"issue":"9","key":"2151_CR22","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s11010-022-04433-0","volume":"477","author":"M Kulbay","year":"2022","unstructured":"Kulbay M, et al. Energetic metabolic reprogramming in Jurkat DFF40-deficient cancer cells. Mol Cell Biochem. 2022;477(9):2213\u201333.","journal-title":"Mol Cell Biochem"},{"issue":"2","key":"2151_CR23","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.3892\/mmr.2015.3567","volume":"12","author":"JH Wang","year":"2015","unstructured":"Wang JH, et al. Downregulation of sprouty homolog 2 by microRNA-21 inhibits proliferation, metastasis and invasion, however promotes the apoptosis of multiple myeloma cells. Mol Med Rep. 2015;12(2):1810\u20136.","journal-title":"Mol Med Rep"},{"issue":"9","key":"2151_CR24","first-page":"10635","volume":"8","author":"W Feng","year":"2015","unstructured":"Feng W, et al. Establishment of stable multiple myeloma cell line with overexpressed PDCD5 and its proapoptosis mechanism. Int J Clin Exp Pathol. 2015;8(9):10635\u201343.","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"2151_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41389-024-00522-5","volume":"13","author":"M Gao","year":"2024","unstructured":"Gao M, et al. Activated platelet-derived Exosomal LRG1 promotes multiple myeloma cell growth. Oncogenesis. 2024;13(1):21.","journal-title":"Oncogenesis"},{"issue":"6","key":"2151_CR26","doi-asserted-by":"publisher","first-page":"464","DOI":"10.14740\/wjon1681","volume":"14","author":"R Wang","year":"2023","unstructured":"Wang R, et al. Circadian clock REV-ERBs agonist SR9009 induces synergistic antitumor activity in multiple myeloma by suppressing glucose-regulated protein 78-dependent autophagy and lipogenesis. World J Oncol. 2023;14(6):464\u201375.","journal-title":"World J Oncol"},{"issue":"1","key":"2151_CR27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41419-024-06454-7","volume":"15","author":"M Liu","year":"2024","unstructured":"Liu M, et al. The regulations of telomerase reverse transcriptase (TERT) in cancer. Cell Death Dis. 2024;15(1):90.","journal-title":"Cell Death Dis"},{"issue":"3","key":"2151_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cpt.2023.12.004","volume":"2","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Gene mutations in newly diagnosed multiple myeloma patients detected by next-generation sequencing technology. Cancer Pathog Ther. 2024;2(3):205\u201311.","journal-title":"Cancer Pathog Ther"},{"issue":"6","key":"2151_CR29","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker BA, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132(6):587\u201397.","journal-title":"Blood"},{"issue":"11","key":"2151_CR30","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3324\/haematol.2010.023697","volume":"95","author":"L Lode","year":"2010","unstructured":"Lode L, et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica. 2010;95(11):1973\u20136.","journal-title":"Haematologica"},{"issue":"6662","key":"2151_CR31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/34214","volume":"391","author":"H Sakahira","year":"1998","unstructured":"Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature. 1998;391(6662):96\u20139.","journal-title":"Nature"},{"issue":"1","key":"2151_CR32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.abb.2007.09.007","volume":"468","author":"GR Dahal","year":"2007","unstructured":"Dahal GR, et al. Caspase-2 cleaves DNA fragmentation factor (DFF45)\/inhibitor of caspase-activated DNase (ICAD). Arch Biochem Biophys. 2007;468(1):134\u20139.","journal-title":"Arch Biochem Biophys"},{"issue":"45","key":"2151_CR33","doi-asserted-by":"publisher","first-page":"31617","DOI":"10.1074\/jbc.M114.583542","volume":"289","author":"K Samejima","year":"2014","unstructured":"Samejima K, et al. Auxin-induced rapid degradation of inhibitor of caspase-activated DNase (ICAD) induces apoptotic DNA fragmentation, caspase activation, and cell death: a cell suicide module. J Biol Chem. 2014;289(45):31617\u201323.","journal-title":"J Biol Chem"},{"issue":"8","key":"2151_CR34","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/febs.13970","volume":"284","author":"BD Larsen","year":"2017","unstructured":"Larsen BD, Sorensen CS. The caspase-activated dnase: apoptosis and beyond. FEBS J. 2017;284(8):1160\u201370.","journal-title":"FEBS J"},{"issue":"10","key":"2151_CR35","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41419-019-1950-1","volume":"10","author":"M Chollat-Namy","year":"2019","unstructured":"Chollat-Namy M, et al. The pharmalogical reactivation of p53 function improves breast tumor cell Lysis by granzyme B and NK cells through induction of autophagy. Cell Death Dis. 2019;10(10):695.","journal-title":"Cell Death Dis"},{"issue":"10","key":"2151_CR36","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.trecan.2020.05.006","volume":"6","author":"DA Alagpulinsa","year":"2020","unstructured":"Alagpulinsa DA, et al. Genomic instability in multiple myeloma. Trends Cancer. 2020;6(10):858\u201373.","journal-title":"Trends Cancer"},{"issue":"9","key":"2151_CR37","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.3390\/cancers13092125","volume":"13","author":"MC Liebl","year":"2021","unstructured":"Liebl MC, Hofmann TG. The role of p53 signaling in colorectal cancer. Cancers (Basel), 2021;13(9):2125.","journal-title":"Cancers (Basel)"},{"issue":"13","key":"2151_CR38","doi-asserted-by":"publisher","first-page":"9200","DOI":"10.1074\/jbc.M112.411371","volume":"288","author":"V Iglesias-Guimarais","year":"2013","unstructured":"Iglesias-Guimarais V, et al. Chromatin collapse during caspase-dependent apoptotic cell death requires DNA fragmentation factor, 40-kDa subunit-\/caspase-activated deoxyribonuclease-mediated 3\u2019-OH single-strand DNA breaks. J Biol Chem. 2013;288(13):9200\u201315.","journal-title":"J Biol Chem"},{"issue":"11","key":"2151_CR39","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/15384101.2021.1919830","volume":"20","author":"M Guo","year":"2021","unstructured":"Guo M, et al. Apoptosis detection: a purpose-dependent approach selection. Cell Cycle. 2021;20(11):1033\u201340.","journal-title":"Cell Cycle"},{"issue":"6","key":"2151_CR40","doi-asserted-by":"publisher","first-page":"118688","DOI":"10.1016\/j.bbamcr.2020.118688","volume":"1867","author":"A Boice","year":"2020","unstructured":"Boice A, Bouchier-Hayes L. Targeting apoptotic caspases in cancer. Biochim Biophys Acta Mol Cell Res. 2020;1867(6):118688.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"2151_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.dnarep.2016.04.008","volume":"42","author":"A Karimian","year":"2016","unstructured":"Karimian A, Ahmadi Y, Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst). 2016;42:63\u201371.","journal-title":"DNA Repair (Amst)"},{"issue":"14","key":"2151_CR42","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.3390\/cancers14143330","volume":"14","author":"RD Parrondo","year":"2022","unstructured":"Parrondo RD, Paulus A, Ailawadhi S. Updates in the use of BCL-2-family small molecule inhibitors for the treatment of relapsed\/refractory multiple myeloma. Cancers (Basel), 2022. 14(14):3330.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2151_CR43","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1182\/blood.V88.5.1805.1805","volume":"88","author":"Y Tu","year":"1996","unstructured":"Tu Y, et al. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood. 1996;88(5):1805\u201312.","journal-title":"Blood"},{"issue":"5","key":"2151_CR44","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","volume":"15","author":"EA Punnoose","year":"2016","unstructured":"Punnoose EA, et al. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 2016;15(5):1132\u201344.","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"2151_CR45","doi-asserted-by":"publisher","first-page":"9873","DOI":"10.1074\/jbc.M111.312694","volume":"287","author":"SK Niture","year":"2012","unstructured":"Niture SK, Jaiswal AK. Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem. 2012;287(13):9873\u201386.","journal-title":"J Biol Chem"},{"issue":"24","key":"2151_CR46","doi-asserted-by":"publisher","first-page":"e0139921","DOI":"10.1128\/JVI.01399-21","volume":"95","author":"YJ Kim","year":"2021","unstructured":"Kim YJ, et al. Inhibitors of Anti-apoptotic Bcl-2 family proteins exhibit potent and broad-spectrum anti-mammarenavirus activity via cell cycle arrest at G0\/G1 phase. J Virol. 2021;95(24):e0139921.","journal-title":"J Virol"},{"issue":"9","key":"2151_CR47","doi-asserted-by":"publisher","first-page":"e106571","DOI":"10.1371\/journal.pone.0106571","volume":"9","author":"BC Koehler","year":"2014","unstructured":"Koehler BC, et al. Pan-Bcl-2 inhibitor Obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells. PLoS ONE. 2014;9(9):e106571.","journal-title":"PLoS ONE"},{"issue":"9","key":"2151_CR48","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nrm2952","volume":"11","author":"SW Tait","year":"2010","unstructured":"Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11(9):621\u201332.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"2151_CR49","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s10495-014-1051-7","volume":"20","author":"M Kvansakul","year":"2015","unstructured":"Kvansakul M, Hinds MG. The Bcl-2 family: structures, interactions and targets for drug discovery. Apoptosis. 2015;20(2):136\u201350.","journal-title":"Apoptosis"},{"issue":"20","key":"2151_CR50","doi-asserted-by":"publisher","first-page":"19836","DOI":"10.1074\/jbc.M414358200","volume":"280","author":"D Milhas","year":"2005","unstructured":"Milhas D, et al. Caspase-10 triggers bid cleavage and caspase cascade activation in FasL-induced apoptosis. J Biol Chem. 2005;280(20):19836\u201342.","journal-title":"J Biol Chem"},{"issue":"4","key":"2151_CR51","first-page":"1271","volume":"41","author":"D Kunze","year":"2012","unstructured":"Kunze D, et al. Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells. Int J Oncol. 2012;41(4):1271\u20137.","journal-title":"Int J Oncol"},{"key":"2151_CR52","doi-asserted-by":"publisher","first-page":"35223","DOI":"10.1038\/srep35223","volume":"6","author":"TL Reddy","year":"2016","unstructured":"Reddy TL, et al. Simultaneous delivery of paclitaxel and Bcl-2 SiRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma. Sci Rep. 2016;6:35223.","journal-title":"Sci Rep"},{"issue":"6","key":"2151_CR53","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/jpm11060463","volume":"11","author":"M Lasica","year":"2021","unstructured":"Lasica M, Anderson MA. Review of venetoclax in CLL, AML and multiple myeloma. J Pers Med, 2021;11(6):463.","journal-title":"J Pers Med"},{"issue":"20","key":"2151_CR54","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.3390\/cancers15204957","volume":"15","author":"J Xu","year":"2023","unstructured":"Xu J et al. Current advances and future strategies for BCL-2 inhibitors: potent weapons against cancers. Cancers (Basel), 2023;15(20):4957.","journal-title":"Cancers (Basel)"},{"key":"2151_CR55","doi-asserted-by":"publisher","first-page":"717919","DOI":"10.1155\/2014\/717919","volume":"2014","author":"PJ Teoh","year":"2014","unstructured":"Teoh PJ, Chng WJ. p53 abnormalities and potential therapeutic targeting in multiple myeloma. Biomed Res Int. 2014;2014:717919.","journal-title":"Biomed Res Int"},{"issue":"6","key":"2151_CR56","doi-asserted-by":"publisher","first-page":"567","DOI":"10.4161\/cbt.10.6.12535","volume":"10","author":"MN Saha","year":"2010","unstructured":"Saha MN, Jiang H, Chang H. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways. Cancer Biol Ther. 2010;10(6):567\u201378.","journal-title":"Cancer Biol Ther"},{"issue":"10","key":"2151_CR57","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1158\/1535-7163.MCT-12-0135","volume":"11","author":"RJ Jones","year":"2012","unstructured":"Jones RJ, et al. Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA. Mol Cancer Ther. 2012;11(10):2243\u201353.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"2151_CR58","doi-asserted-by":"publisher","first-page":"8091","DOI":"10.1074\/jbc.275.11.8091","volume":"275","author":"H Sakahira","year":"2000","unstructured":"Sakahira H, Iwamatsu A, Nagata S. Specific chaperone-like activity of inhibitor of caspase-activated DNase for caspase-activated DNase. J Biol Chem. 2000;275(11):8091\u20136.","journal-title":"J Biol Chem"},{"issue":"6662","key":"2151_CR59","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/34112","volume":"391","author":"M Enari","year":"1998","unstructured":"Enari M, et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 1998;391(6662):43\u201350.","journal-title":"Nature"},{"issue":"3","key":"2151_CR60","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s10495-005-1900-5","volume":"10","author":"H Kanouchi","year":"2005","unstructured":"Kanouchi H, et al. Large complex formation of the inhibitor of caspase-activated DNase. Apoptosis. 2005;10(3):651\u20136.","journal-title":"Apoptosis"},{"issue":"16","key":"2151_CR61","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1111\/j.1742-4658.2012.08673.x","volume":"279","author":"D Kutscher","year":"2012","unstructured":"Kutscher D, et al. Identification of ICAD-derived peptides capable of inhibiting caspase-activated DNase. FEBS J. 2012;279(16):2917\u201328.","journal-title":"FEBS J"},{"key":"2151_CR62","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/978-1-4939-8997-3_20","volume":"1914","author":"SWZ Olechnowicz","year":"2019","unstructured":"Olechnowicz SWZ, Edwards CM. Animal models of multiple myeloma. Methods Mol Biol, 2019;1914:349\u2013360.","journal-title":"Methods Mol Biol"},{"issue":"7","key":"2151_CR63","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3390\/ph17070944","volume":"17","author":"F Bigi","year":"2024","unstructured":"Bigi F et al. Impact of Anti-CD38 monoclonal antibody therapy on CD34\u2009+\u2009Hematopoietic stem cell mobilization, collection, and engraftment in multiple myeloma patients\u2013a systematic review. Pharmaceuticals (Basel), 2024;17(7):944.","journal-title":"Pharmaceuticals (Basel)"},{"key":"2151_CR64","doi-asserted-by":"publisher","first-page":"102030","DOI":"10.1016\/j.scr.2020.102030","volume":"49","author":"SJ Lee","year":"2020","unstructured":"Lee SJ, et al. Generation of normal induced pluripotent stem cell line KUMCi002-A from bone marrow CD34\u2009+\u2009cells of patient with multiple myeloma disease having 13q deletion and IGH translocation. Stem Cell Res. 2020;49:102030.","journal-title":"Stem Cell Res"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-025-02151-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-025-02151-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-025-02151-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T15:04:31Z","timestamp":1767884671000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-025-02151-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2151"],"URL":"https:\/\/doi.org\/10.1007\/s00011-025-02151-z","relation":{},"ISSN":["1420-908X"],"issn-type":[{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experimental protocols were strictly conducted in accordance with the guidelines for the care and use of laboratory animals issued by the National Institutes of Health, and were approved by the Animal Experiment Ethics Committee of The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People\u2019s Hospital of Shenzhen (2022027DW). Every effort was made to reduce the number of animals and minimize their suffering.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The work described has not been published previously, that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Submission declaration and verification"}}],"article-number":"16"}}